95 related articles for article (PubMed ID: 7963984)
1. [Historical background of Parkinson's disease: on cellular degeneration of the substantia nigra].
Tanaka J; Fukuda T
Nihon Naika Gakkai Zasshi; 1994 Apr; 83(4):528-32. PubMed ID: 7963984
[No Abstract] [Full Text] [Related]
2. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
4. A brief history of parkinsonism.
Duvoisin RC
Neurol Clin; 1992 May; 10(2):301-16. PubMed ID: 1584174
[TBL] [Abstract][Full Text] [Related]
5. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
6. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship.
Parent M; Parent A
Can J Neurol Sci; 2010 May; 37(3):313-9. PubMed ID: 20481265
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
[TBL] [Abstract][Full Text] [Related]
8. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
9. Iron and ferritin in substantia nigra in Parkinson's disease.
Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
[No Abstract] [Full Text] [Related]
10. The history of drugs for the treatment of Parkinson's disease.
Kapp W
J Neural Transm Suppl; 1992; 38():1-6. PubMed ID: 1491242
[TBL] [Abstract][Full Text] [Related]
11. Degeneration of the centré median-parafascicular complex in Parkinson's disease.
Henderson JM; Carpenter K; Cartwright H; Halliday GM
Ann Neurol; 2000 Mar; 47(3):345-52. PubMed ID: 10716254
[TBL] [Abstract][Full Text] [Related]
12. The neuromythology of Parkinson's Disease.
Calne DB; Mizuno Y
Parkinsonism Relat Disord; 2004 Jul; 10(5):319-22. PubMed ID: 15196512
[TBL] [Abstract][Full Text] [Related]
13. Topographical alterations of the midbrain and the substantia nigra following unilateral posteroventral pallidotomy in patients with Parkinson's disease using routine and multishot diffusion-weighted magnetic resonance imaging.
Adachi M; Kurimura M; Saito S; Hosoya T; Kayama T; Kato T
Neuroradiology; 2002 Jul; 44(7):579-85. PubMed ID: 12136359
[TBL] [Abstract][Full Text] [Related]
14. [Aging and Parkinson's disease].
Tohgi H; Abe T; Takahashi S
No To Shinkei; 1991 Aug; 43(8):713-9. PubMed ID: 1931254
[No Abstract] [Full Text] [Related]
15. [Incidental occurrence of Lewy bodies in the brains of elderly patients--the relevance to aging and Parkinson's disease].
Wakabayashi K; Takahashi H; Oyanagi K; Ikuta F
No To Shinkei; 1993 Nov; 45(11):1033-8. PubMed ID: 8135950
[TBL] [Abstract][Full Text] [Related]
16. What process causes nigral cell death in Parkinson's disease?
Jenner P
Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report.
Hughes AJ; Daniel SE; Lees AJ
Mov Disord; 1991; 6(4):342-6. PubMed ID: 1758453
[TBL] [Abstract][Full Text] [Related]
18. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
19. Effects of intracerebral transplantation of immature substantia nigra in rats with experimentally induced Parkinson's disease. I Comparative evaluation of two models of Parkinson's disease induced by unilateral stereotaxic lesion of the substantia nigra with electrocoagulation and with 6-hydroxydopamine.
Dymecki J; Markiewicz D; Półtorak M; Puciłowski O; Kostowski W; Bidziński A
Neuropatol Pol; 1985; 23(2):167-79. PubMed ID: 3930994
[No Abstract] [Full Text] [Related]
20. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?
Ziv I; Barzilai A; Offen D; Stein R; Achiron A; Melamed E
Adv Neurol; 1996; 69():229-33. PubMed ID: 8615132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
